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Effects of recombinant human
erythropoietin on cognition and neural
activity in remitted patients with mood
disorders and first-degree relatives of
patients with psychiatric disorders: a study
protocol for a randomized controlled trial
Jeff Zarp Petersen1,2, Lejla Sjanic Schmidt1, Maj Vinberg1,6, Martin Balslev Jørgensen1,6, Ida Hageman1,
Hannelore Ehrenreich3,4, Gitte Moos Knudsen5,6, Lars Vedel Kessing1,6 and Kamilla Woznica Miskowiak1,2*
Abstract
Background: Bipolar disorder (BD) and unipolar disorder (UD) are associated with cognitive deficits and
abnormal neural activity in a “cognitive control network.” There is an increased prevalence of cognitive
dysfunction in psychiatric patients’ first-degree relatives, which constitutes a risk factor for psychiatric illness
onset. However, there is no treatment with enduring pro-cognitive efficacy. We found preliminary evidence
for beneficial effects of eight weekly doses of recombinant human erythropoietin (EPO) on cognition in BD
in a recent randomized controlled trial (RCT). The present RCT consists of two sub-studies that extend our
previous work by investigating important novel aspects: (1) the effects of 12 weekly doses of EPO on
cognition in first-degree relatives of patients with BD, UD, or schizophrenia; and (2) the effects of extending
the treatment schedule from 8 to 12 weeks in remitted patients with BD or UD; and (3) assessment of early
treatment-associated neural activity changes that may predict cognitive improvement.
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* Correspondence: kamilla.woznica.miskowiak@regionh.dk;
kamilla.miskowiak@regionh.dk
1Neurocognition and Emotion in Affective Disorder (NEAD) Group,
Copenhagen Affective Disorder Research Centre (CADIC), Psychiatric Centre
Copenhagen, Copenhagen University Hospital, Blegdamsvej 9, DK-2100
Copenhagen, Denmark
2Department of Psychology, University of Copenhagen, Øster Farimagsgade
2A, DK-1353 Copenhagen, Denmark
Full list of author information is available at the end of the article
© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Petersen et al. Trials          (2018) 19:611 
https://doi.org/10.1186/s13063-018-2995-7
(Continued from previous page)
Methods: The trial comprises two parallel sub-studies with randomized, controlled, double-blinded, parallel
group designs. First-degree relatives (sub-study 1; n = 52) and partially or fully remitted patients with BD or
UD (sub-study 2; n = 52) with objectively verified cognitive dysfunction are randomized to receive weekly
high-dose EPO (40,000 IU/mL) or placebo (saline) infusions for 12 weeks. Assessments of cognition and mood
are conducted at baseline, after two weeks of treatment, after treatment completion, and at six-month follow-
up. Functional magnetic resonance imaging (fMRI) is conducted at baseline and after two weeks of treatment.
Psychosocial function is assessed at baseline, after treatment completion and six-month follow-up. The primary outcome
is change in a cognitive composite score of attention, verbal memory, and executive functions. Statistical power of ≥ 80%
is reached to detect a clinically relevant between-group difference by including 52 first-degree relatives and 52 patients
with BD or UD, respectively. Behavioral data are analyzed with an intention-to-treat approach using mixed models. fMRI
data are analyzed with the FMRIB Software Library.
Discussion: If this trial reveals pro-cognitive effects of EPO, this may influence future treatment of mood disorders and/or
preventive strategies in at-risk populations. The fMRI analyses may unravel key neurobiological targets for pro-cognitive
treatment.
Trial registration: ClinicalTrials.gov, NCT03315897. Registered on 20 October 2017.
Keywords: Bipolar disorder, Depression, Cognition, Cognitive dysfunction, Erythropoietin, Pro-cognitive efficacy, Prefrontal
cortex, Functional magnetic resonance imaging, Biomarker
Background
Cognitive deficits occur in moderate to severe degree in pa-
tients with bipolar disorder (BD) and unipolar disorder
(UD) [1–6]. These deficits are not only present during acute
episodes, but commonly persist after remission [1–7]. This
negatively affects patients’ quality of life, recovery rates, and
socio-occupational functioning [6, 8–12] of which reduced
work capacity is the largest area of socioeconomic burden
[13, 14]. A higher occurrence of mild to moderate deficits
has also been detected in BD, UD, and schizophrenia pa-
tients’ unaffected first-degree relatives compared with
healthy controls with no first-degree family history of psy-
chiatric disorder [15–19]. These impairments increase the
risk of psychiatric illness onset in these individuals [20].
Cognition is therefore a key treatment priority in patients
with mood disorders and genetically predisposed individ-
uals [21]. Nevertheless, there are no existing treatments
with solid and enduring efficacy on cognitive dysfunction in
these populations. New candidate treatments have only
produced disappointing or preliminary results [22]. This is
partially related to major methodological challenges, includ-
ing the absence of a sensitive brain-based biomarker model
to detect the efficacy of candidate treatments in phase 1
and 2 clinical trials [23]. In fact, candidate drug treatment
screening typically relies on animal models with com-
pounds being directly moved into large-scale, costly clinical
efficacy trials, in cases of beneficial effects in the animal
model. However, detection of pro-cognitive efficacy in ani-
mal models has poor predictive value in clinical trials [24],
which underlines the need for a more valid, sensitive bio-
marker model for pro-cognitive efficacy. Emerging evidence
highlights blood-oxygen-level dependent (BOLD) func-
tional magnetic resonance imaging (fMRI) response in the
prefrontal cortex (PFC) as a promising biomarker for cog-
nitive dysfunction and early cognitive improvement. In
particular, aberrant (primarily hypo-) activity in the dorso-
lateral and medial PFC (dlPFC and mPFC) during working
memory and episodic encoding tasks is the most reprodu-
cible neural marker of cognitive dysfunction across neuro-
psychiatric disorders, including BD, UD, schizophrenia,
and genetically predisposed individuals [25–31]. This ab-
errant activity reflects difficulties with selecting and main-
taining stimuli in working memory and strategic memory
encoding [32]. Reversal of aberrant dorsal prefrontal activ-
ity may therefore constitute a promising neural biomarker
for cognitive improvement.
Preclinical and clinical studies point to erythropoietin
(EPO) as one of the most promising candidate cognitive
enhancement treatments [33]. EPO is produced in the
brain where it exerts neurotrophic and neuroprotective
actions and plays a central role in cognitive functioning
[33–37]. Clinical studies have found that repeated sys-
tematically administered high-dose recombinant human
EPO versus placebo (saline) improves attention, mem-
ory, and executive functions after 8–12 weeks of treat-
ment across neuropsychiatric disorders, including
multiple sclerosis, Parkinson’s disease, schizophrenia,
treatment-resistant depression (TRD; defined as failure
to respond to ≥ 2 different types of antidepressant treat-
ments given in sufficient doses over sufficient time [38]),
and BD [39–43]. In particular, two randomized
placebo-controlled trials from our group revealed that
eight weekly EPO infusions improved several cognitive
domains in patients with BD and TRD [39, 40]. This was
accompanied by increased activity in dlPFC and dor-
somedial PFC (dmPFC) during working memory and
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episodic encoding tasks [44, 45]. Notably, a single dose
of EPO enhances cognition-related dlPFC and dmPFC
activity without producing any change in red blood cells
[46, 47]. This suggests that the EPO-associated increase
in task-related dorsal PFC (dPFC) reflects direct effects
of EPO in the brain. Taken together, these preliminary
findings point to EPO as a promising cognition treat-
ment and to neuronal activity change in the dPFC as a
key neural correlate of treatment-related improvement
of cognition. Nevertheless, our EPO trial had a number
of methodological limitations [39, 40]. First, cognitive
dysfunction was not verified with an objective (i.e.
neuropsychological) measure before enrollment of par-
ticipants. This is problematic since we found in post-hoc
analyses that objective cognitive impairment at baseline
was the strongest predictor of treatment success on cogni-
tion [48, 49]. Second, the primary outcome was a single
measure of verbal memory, which contrasts with the re-
cently published recommendations by the International
Society for Bipolar Disorders (ISBD) Targeting Cognition
Task Force that the primary outcome in cognition trials
should be a broad cognitive composite score spanning at-
tention, memory, and executive function [50]. Third, the
lack of long-term follow-up assessment hampered insight
into whether treatment-associated cognitive improvement
was long-lasting. Fourth, we had not assessed functional
capacity in the patient sample and thus had no insight into
whether the EPO-related improvement of cognition trans-
lated into better functional capacity.
Aims and hypotheses
The aims of the present EPO trial are threefold. First, we
aim to investigate whether 12 weekly recombinant hu-
man EPO infusions ameliorate cognitive impairments in
first-degree relatives without psychotic or mood disor-
ders to patients with BD, recurrent UD, or schizophrenia
(sub-study 1). This will allow for the first time to judge
the disease-independent response of inherent cognitive
genetic traits. Second, we will examine whether a longer
treatment period is associated with similar or stronger
cognitive improvement in remitted patients with BD or
recurrent UD (defined as ≥ 2 treatment-requiring de-
pressive episodes) (sub-study 2). Third, we will explore
with fMRI the early neuronal changes that are predictive
of subsequent clinically relevant cognitive improvement
across these groups. We hypothesize that:
1. 12 weekly EPO infusions improve cognition in first-
degree relatives and remitted patients with BD or
recurrent UD in comparison with saline.
2. EPO versus saline-treated participants will display
early cognition-related neural activity in dorsal PFC
in the direction of the activity in healthy controls,
which will correlate with cognitive improvement.
Methods and design
Participants
We will recruit 52–58 first-degree relatives without
psychotic or mood disorders to patients with BD, recur-
rent UD, or schizophrenia (sub-study 1) and 52–58 pa-
tients with BD or recurrent UD in partial or full
remission (defined as a score of ≤ 14 on the Hamilton
Depression Rating Scale 17-items (HDRS-17; [51]) and
the Young Mania Rating Scale (YMRS; [52]) (sub-study
2) with objectively verified cognitive dysfunction to ob-
tain a complete dataset for 52 participants per sub-study
(assuming a 10% drop-out rate from inclusion to treat-
ment completion). Participants will be recruited from
psychiatric centers in The Mental Health Services in the
Capital Region of Denmark, consultant psychiatrists in
the Capital Region of Denmark, as well as through ad-
vertisements on relevant websites. Within each
sub-study, half of the participants will be randomized to
receive active treatment (n = 26–29), while the other half
will receive placebo (n = 26–29).
Eligible participants are aged 18–65 years, have fluent
Danish skills, and display objectively verified cognitive
dysfunction according to the Screen for Cognitive Im-
pairment in Psychiatry (SCIP) [53–55]. Specifically, par-
ticipants must have a total SCIP score of ≤ 77, which
provides adequate sensitivity and specificity for cognitive
impairment (86% and 70%, respectively) [53], or have a
score corresponding to ≥ 1 standard deviation (SD)
below the norm on ≥ 2 SCIP subtests [50, 53]. For indi-
viduals with a verbal IQ ≥ 120 (i.e. ≥ 1 SD higher than
the average IQ in age-matched healthy control partici-
pants) according to the Danish Adult Reading Test
(DART [56]), the adjusted inclusion criterion is a score >
1 SD below the norm on ≥ 1 SCIP subtest. In this way,
cognitive impairment is to some degree established with
reference to participants’ premorbid IQ in accordance
with recent guidelines by the ISBD Targeting Cognition
Task Force [50].
Patients are eligible if an ICD-10 diagnosis of BD or
recurrent UD is confirmed with the Schedules for Clin-
ical Assessment in Neuropsychiatry (SCAN) [57]. The
maximum daily use of benzodiazepines allowed is
22.5 mg oxazepam (benzodiazepines will be avoided on
the day of neuropsychological assessments). Patients’
medication must remain unchanged during the study
period, unless a change of medication is deemed neces-
sary by their treating psychiatrist. First-degree relatives
are allowed to have minor psychiatric disorders (defined
as ICD-10 codes > F40), since these individuals are at
particular risk of (major) psychiatric illness onset. Specif-
ically, first-degree relatives are eligible even if diagnosed
with a psychiatric disorder categorized within the
ICD-10 as F40–49 (anxiety, dissociative, stress-related,
somatoform, and other non-psychotic mental disorders),
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F50–59 (behavioral syndromes associated with physio-
logical disturbances and physical factors), and F60–69
(disorders of adult personality and behavior) codes, as
long as these disorders only influence their current state
to a minor degree (i.e. they are well-treated at the time
of inclusion).
Exclusion criteria for both sub-studies are individuals
with intellectual disability (defined as an estimated IQ <
70) [50], schizophrenia or schizoaffective disorder,
neurological disorder (including dementia), current alcohol
or substance abuse (up to 3 months prior to inclusion), or
history of head trauma. To ensure safety of EPO treatment
throughout the study, candidates are also excluded if they
have significant medical conditions (e.g. heart disease, dia-
betes, renal failure, untreated/insufficiently treated hyper-
tension, malignancies, and/or thromboses), personal or
first-degree family history of epilepsy or thromboembolic
events, have received electroconvulsive therapy (ECT)
three months before participation, are dyslexic, use
contraceptive medications, smoke, are pregnant, or are
breastfeeding. Regarding fMRI assessments, participants
are not eligible if they suffer from claustrophobia or have
a pacemaker and/or other metal implants inside their bod-
ies. Participants, who do not meet these fMRI inclusion
criteria will not be excluded from the trial per se, but only
from the two fMRI assessments.
These criteria are similar to the procedures in our
previous studies [39, 40, 58]. To ensure that partici-
pants receive a sufficient concentration of EPO, can-
didates are excluded if they weigh < 45 or > 95 kg or
are overweight (BMI > 30). Participants must be able
to provide written informed consent to be included in
the study. These procedures are in accordance with
the ethical standards of the Danish Research Ethics
Committee for the Capital Region of Denmark (proto-
col number H-16043370) and The Danish Data Pro-
tection Agency Capital Region of Denmark (protocol
number RHP-2017-020). See Additional file 1 (SPIRIT
2013 Checklist) for a trial protocol checklist.
Setting
Participants will receive intravenous infusions of either
recombinant human EPO (Epoetin alpha; Eprex;
40,000 IU/mL) or placebo (1 mL NaCl) diluted with
100 mL saline (0.9% NaCl) administered for 15 min once a
week (7 ± 2 days) during a 12-week study period at the
Copenhagen Affective Disorder Research Center (CADIC),
Psychiatric Centre Copenhagen, Rigshospitalet. The EPO
doses are similar to those found to be effective for modu-
lating neural and cognitive function with short-term ad-
ministration [46] and for enhancing cognition with
long-term treatment [39, 40, 42, 59]. Outcome assessments
are also carried out at Psychiatric Centre Copenhagen and
Neurobiology Research Unit (NRU), Rigshospitalet.
Study design and procedures
The trial has a randomized, double-blinded, placebo-
controlled, parallel group design. The study design com-
prises four major assessments (baseline, week 3, week
13, and a six-month follow-up after treatment comple-
tion) and weekly safety monitoring and study medication
infusions during the 12-week treatment period. Partici-
pants will be informed about the study and given a par-
ticipant information sheet. Before undergoing eligibility
assessments, participants provide written informed
consent, which will be obtained by one of the named
authors.
The baseline assessment is divided into two days, 1–
3 days apart for practical reasons and to avoid attrition.
On the first day of the baseline assessment, participants
are mood rated with the HDRS-17 and YMRS to ensure
remission and afterwards complete an fMRI scan at
Copenhagen University Hospital, Rigshospitalet. On the
second baseline day, participants attend Psychiatric Centre
Copenhagen for a fasting research blood test (peripheral
biomarker measure) followed by an assessment of cogni-
tive functions with a neuropsychological test battery, ver-
bal IQ (assessed with the Danish Adult Reading Test;
DART [56]), and filling in questionnaires concerning sub-
jective cognitive complaints, quality of life, level of func-
tioning, and functional capacity, as well as depression and
mania symptom severity ratings. Functional capacity will
be assessed using a clinician-rated interview and a
performance-based task. Mood ratings are performed with
the HDRS-17 [51] and the YMRS [52]. After two weeks of
treatment (i.e. two doses of EPO or saline), fMRI scan, re-
search blood samples, neuropsychological testing, mood
ratings, and questionnaires on subjective cognitive diffi-
culties are repeated. After treatment completion (week 13)
and at the six-month follow-up, the neuropsychological
tests, questionnaires concerning subjective cognitive com-
plaints, quality of life, and functional capacity (self-re-
ported and performance-based) are repeated. Research
blood samples are collected in week 13, but not at the
six-month follow-up. Sleep quantity and quality in the
past three days is assessed before each of the four major
assessment time points and with online self-rating using
the Pittsburgh Sleep Quality Inventory (PSQI) [60] asses-
sing sleep quality one week before the baseline, week 3,
week 13, and the six-month follow-up assessment. Blood
samples are collected at baseline and weeks 3 and 13 for
assessment of potential blood-based biomarkers of
pro-cognitive effects. An intermediate mood symptom rat-
ing for patients (sub-study 2) is performed at week 7 to as-
sess whether they are in (partial) remission throughout
the study period. To ensure safety, we conduct weekly
monitoring, comprising thorough medical examinations
and blood test evaluations, for the duration of the treat-
ment course and in weeks 13 and 15. Pregnancy tests are
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mandatory for and will be performed on fertile female par-
ticipants before the first study medication infusions and
every second week during the active treatment period.
Blood screening and thorough medical examinations are
undertaken at baseline, weekly throughout the 12-week
treatment period as well as one and three weeks after
treatment completion to continuously monitor red blood
cell levels and ensure participant safety.
EPO will be kept at 2–8 °C during transport and stor-
age to reduce the risk of damaging the medication and
potential related adverse side effects. EPO will be dis-
solved in 100 mL saline and infusions will be given
intravenously over 15 min to reduce the possibility of
acute allergic reactions. If blood test analyses reveal sig-
nificantly increased hematocrit (men: > 50%; women: >
48%) at two consecutive measurements within the same
week, bloodletting (450 mL) will be performed on a
weekly basis with no cessation of treatment before
hematocrit values are normalized. Patients are therefore
asked to regularly drink plenty of water to avoid “pseu-
do”-increases in hematocrit. In cases of significant in-
crease in thrombocytes (> 400 billion/L) or drop in
reticulocytes (ERC(B) < 1 × 10− 3), two repeated controls
will be performed in the following week. If thrombocyte
and/or reticulocyte values remain abnormal, participants
will be withdrawn from further study participation and
monitored with weekly medical examinations and blood
samples until values are stabilized. If necessary, these
participants will be hospitalized for observation. Lists of
any pseudo-anonymized outcome data collected for par-
ticipants who discontinue or deviate from further study
participation will be kept in a locked cabinet.
Randomization and blinding
The independent Pharma Consulting Group AB
(www.pharmaconsultinggroup.com) has conducted block
randomization for each sub-study group. Randomization
is performed utilizing a 1:1 allocation ratio. Treatment
groups will be stratified for gender and age (sub-study 1:
< or > 30 years; sub-study 2: < or > 35 years). At the time
of enrolment, diagnosis, gender, and date of birth are
registered in order to determine the appropriate stratum
to which the participant belongs. Study identification
numbers will be given consecutively within each
stratum. To ensure blinding of outcome-assessors,
sealed randomization envelopes are kept in a locked cab-
inet only accessible to study personnel responsible for
preparing the study medication, who are not involved in
evaluation of the efficacy parameters or regular inter-
action with participants (i.e. the study nurse and PhD
student). Double-blinding is achieved during infusion
through injection of 1 mL colorless recombinant human
EPO (Eprex; 40,000 IU; Janssen-Cilag) or saline (NaCl
0.9%) is injected into a standard 100 mL saline (NaCl
0.9%) infusion bag that will be given to the blinded re-
search nurse or physician administering the study medi-
cation within 1 h before drug administration. The
weekly safety monitoring of blood tests and side effects
will be completed by medical doctors not involved in
outcome assessments. To maintain blinding, participants
are instructed to not talk about any symptoms or poten-
tial physical side effects associated with high-dose EPO
treatment (e.g. increased hematocrit or bloodletting)
with the study personnel who administer infusions or
are involved in outcome assessments. At the last
follow-up assessment (after six months), participants
and blinded study personnel are asked to guess whether
they believe they received EPO or saline treatment dur-
ing their study participation. This is done to evaluate al-
location concealment. Unblinding is permissible for
safety reasons in cases of side-effects or serious adverse
events likely or directly related to the study medication.
The procedure for revealing a participant’s allocated
intervention during the trial involves opening his or her
randomization envelope. In these cases, it is LSS, MV, or
LVK’s sovereign decision, whether the randomization
code should be broken. The study is monitored by the
Good Clinical Practice Unit (GCP) at the Copenhagen
University Hospital (www.gcp-enhed.dk/kbh).
Outcome assessments
For an overview of outcome assessment frequency and
timing, see Fig. 1. The outcome measures listed below
are consistent with the latest recommendations from the
ISBD Task Force [50] suggesting the inclusion of a cog-
nitive composite score as the primary outcome measure,
a single intervention-specific cognitive measure as the
secondary outcome, and multiple individual cognitive
measures as tertiary (i.e. exploratory) outcome measures.
Primary outcome measures
The primary outcome measure is a cognitive composite
score, consisting of neuropsychological tests covering at-
tention, memory, and executive functions. We have pre-
viously demonstrated an improvement on this “speed of
complex cognitive processing” composite measure in pa-
tients with BD after eight weeks of EPO treatment [39].
In the present trial, the specific tests included in the pri-
mary composite outcome measure are the Rey Auditory
Verbal Learning Test (RAVLT) [61, 62], The Repeatable
Battery for the Assessment of Neuropsychological Status
(RBANS) Coding [63], Verbal Fluency with the letter “D”
[64], Wechsler Adult Intelligence Scale (WAIS)-III
Letter-Number Sequencing [65], Trail Making Test Part
B (TMT-B) [66], and Rapid Visual Information Process-
ing (RVP) from the Cambridge Neuropsychological Test
Automated Battery (CANTAB, Cambridge Cognition
Ltd.). To derive the cognitive composite score, we will
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Fig. 1 (See legend on next page.)
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z-transform and sum performance scores from RAVLT
total recall, TMT-B, WAIS-III Letter-Number Sequen-
cing, RBANS Coding, Verbal Fluency (letter “D”), and
RVP speed for correct responses using the mean and SD
from a healthy control group.
Secondary outcome measure
The secondary cognitive outcome measure consists of
the RVP (CANTAB), which revealed particularly strong
effects of EPO in our previous eight-week study [39],
and a functional capacity outcome measure assessed
with the clinician-rated interview Functional Assessment
Short Test (FAST) [67].
Tertiary outcome measures
The tertiary cognitive outcome measure comprises the
RAVLT, RBANS Coding and Digit Span, Verbal Fluency
with the letters “S” and “D” [64], WAIS-III Letter-Number
Sequencing, the One Touch Stockings of Cambridge
(OTS; CANTAB), the Spatial Working Memory (SWM;
CANTAB), as well as the TMT-B and Trail Making Test
Part A (TMT-A) [66]. The tertiary level of psychosocial
functioning outcome are the following questionnaires and
performance-based task: Assessment of Quality of Life
(AQoL) [68], the Cognitive Complaints in Bipolar Dis-
order Rating Assessment (COBRA) [69], Sheehan Disabil-
ity Scale (SDS) [70], the UCSD Performance-Based Skills
Assessment-B (UPSA-B) [71, 72], the World Health
Organization Quality of Life (WHOQOL-BREF) [73], and
the Work and Social Adjustment Scale (WSAS) [74]. His-
tory of early life stress will be assessed with the Childhood
Abuse and Trauma Scale [75] at the time of inclusion.
To minimize learning effects on neuropsychological
test performance at the follow-up assessments, alternate
versions of the RAVLT (original list AB, GeAB, and
Cr-AB) and RBANS Coding and Digit Span (version A
and B) [61–63] are used. These versions will be adminis-
tered in counter-balanced order within each stratum.
Neural biomarkers of potential pro-cognitive effects
To assess whether an early change in neural activity in
the dlPFC and mPFC is predictive of pro-cognitive effi-
cacy, participants will complete MRI scan at baseline
and following two weeks of treatment. The MRI scan
duration is approximately 1.5 h and includes a structural
scan, three functional tasks, including (1) a Strategic
Picture Encoding Task, (2) a Verbal task, and (3) a
Spatial N-back working memory task from our previous
study [45], as well as a checkerboard pattern sequence
and a resting state sequence. The fMRI protocol has
been constructed to evaluate the sensitivity and specifi-
city of potential neural activity change in the dlPFC and
mPFC after two weeks of active treatment and whether
this can predict cognitive improvement after 12 weeks
of treatment.
Exploratory measures of potential pro-cognitive effects
To further increase insight into the underlying neurobio-
logical mechanisms involved in the potential beneficial cog-
nitive effects of EPO, blood samples from baseline, week 3,
and after treatment will be analyzed for the exploratory
purpose of investigating whether baseline levels and/or
changes of peripheral biomarkers, including inflammatory
markers, brain-derived neurotrophic factor (BDNF), and
metabolic parameters (fat and glucose markers), are corre-
lated with cognitive improvement [76–83]. Baseline blood
samples will also be used for assessment of potential influ-
ence of Catechol-O-methyltransferase (COMT: Val158-
Met), BDNF: Val66Met, and EPO and EPO-R genotypes on
the treatment-related change in cognition and neural
activity.
We will perform post-hoc exploratory analyses investi-
gating which demographic, clinical, cognitive, and neural
variables at baseline predict treatment efficacy on the
primary cognitive outcome measure, since there is a
paucity of research into which baseline factors are asso-
ciated with cognitive improvements [84].
Biochemistry
Research blood samples will be transferred to the
Neuropsychiatric Laboratory, Rigshospitalet, and stored
at − 80 °C until use. Measurements will be performed at
Neuropsychiatric Laboratory, Department O, and at De-
partment of Clinical Pharmacology, Rigshospitalet.
Statistical analyses
The threshold for statistical significance is considered p
< 0.05 (two-tailed). For significant results regarding the
primary, secondary, and tertiary measures, relevant ef-
fect sizes will be reported in addition to the p values. All
(See figure on previous page.)
Fig. 1 Schedule of enrolment, interventions, and assessments. EPO erythropoietin, RVP Rapid Visual Information Processing (CANTAB, Cambridge
Cognition Ltd.), FAST Functional Assessment Short Test, RAVLT Rey Auditory Verbal Learning Test, RBANS Repeatable Battery for the Assessment
of Neuropsychological Status, WAIS-III LNS Wechsler Adult Intelligence Scale Version III Letter-Number Sequencing, OTS One Touch Stockings of
Cambridge, SWM Spatial Working Memory, TMT-A Trail Making Test Part A, TMT-B Trail Making Test Part B, AQoL Assessment of Quality of Life,
COBRA Cognitive Complaints in Bipolar disorder Rating Assessment, SDS Sheehan Disability Scale, UPSA-B UCSD Performance-Based Skills
Assessment-B, WHOQOL-BREF World Health Organization Quality of Life, WSAS Work and Social Adjustment Scale, DART Danish Adult Reading
Test, CTQ Childhood Trauma Questionnaire, SCIP Screen for Cognitive Impairment in Psychiatry (Danish version)
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statistical analyses are performed using the Statistical
Package for Social Sciences (SPSS, version 23, IBM Cor-
poration, Armonk, NY, USA).
Primary, secondary, and tertiary outcome measure analyses
Behavioral data from neuropsychological test score per-
formance, subjective cognitive impairments, quality of
life, level of functioning, psychosocial functioning, and
mood symptoms (i.e. data from the primary, secondary,
and tertiary outcomes) will be analyzed using mixed
models design and intention-to-treat (ITT) analyses in
cases of missing data. Data will be analyzed for every
participant with any assessment. No interim analyses will
be performed.
Functional MRI analyses
Functional MRI data are pre-processed and analyzed
with FMRIB Expert Analysis Tool (FEAT) and the
“randomize” algorithm implemented in FSL (FMRIB
Software Library; www.fmrib.ox.ac.uk/fsl). We will assess
whether early differences between EPO and placebo
groups in task-related neural activity during each of the
three fMRI paradigms after two weeks of treatment (ad-
justed for baseline activity) predict subsequent treatment
efficacy on cognition at treatment completion. Neuro-
psychological test performance and fMRI data from 40
cognitively intact healthy controls without personal or
first-degree relative history of mental illness from the
BIO study [85] is used as external normative data.
Region of interest (ROI) analyses of fMRI data from
the N-back working memory tasks will be carried out to
investigate the effects of EPO on neural activity in
dlPFC. The difference in neural activity between the
EPO and saline groups in week 3 will be investigated by
extracting and analyzing mean percent signal change in
dlPFC adjusted for potential differences in baseline activ-
ity using univariate analysis of covariance (ANCOVA)
and with whole-brain analyses (FEAT) in week 3 (with
adjustment for potential activity differences at baseline).
We will also investigate the hypothesized early dorsal
PFC activity change in response to EPO versus saline
with volume of interest (VOI) for the dorsal PFC. Volume
of interest analyses of dorsal PFC and the hippocampus
are conducted to assess fMRI data from the Strategic Pic-
ture Encoding Task. Finally, exploratory whole-brain ana-
lyses are conducted to assess treatment-related activity
change in other brain regions. Differences in neural activ-
ity between groups will be correlated with potential
change in the primary cognitive composite score at week
3 and after treatment completion. If this correlation is sig-
nificant, multiple regression analyses will be performed
with adjustment for mood symptoms, age, and gender to
assess the potential predictive value of early neural activity
change for potential pro-cognitive efficacy after 12 weeks
of EPO treatment.
Peripheral blood-based biomarker analyses
Post-hoc analyses will be conducted on research blood
sample data collected at baseline, week 3, and week 13
for the exploratory purposes to assess whether potential
efficacy on cognition in response to EPO versus saline is
accompanied by and related to changes in blood-based
biomarkers of inflammation and metabolism.
Sample size and power calculation
Sample size and statistical power has been calculated by
PharmaConsulting Group AB with Statistical Analysis
Software (SAS), based on our previous findings assessing
cognitive effects of weekly infused EPO [48]. The differ-
ence in cognitive change between the EPO and the
saline-treated groups from baseline to after treatment
was 0.5 SD [48]. In this trial, we estimate a clinically
relevant differential change in the primary cognitive
composite score between the EPO and placebo groups
from baseline to week 13 (treatment completion) to be
at least 0.4 SD (corresponding to a moderate effect size)
with a SD of the mean change of 0.5 between these
groups. This is consistent with the recommendations
listed by the ISBD Cognition Task Force [50]. Specific-
ally, the task force indicated that a differential change
between groups of 0.2–0.4 SD on a global composite
score reflects a potentially clinically relevant change,
since this may translate into moderate–large functional
improvement in patients with mood disorders [50]. In
our eight-week EPO trial, the difference regarding
change in the cognitive composite score from baseline
to treatment completion was 0.5 SD between the EPO
and the saline groups [48]. Based on the ISBD task force
recommendations and our earlier findings regarding ef-
fects of longer-term EPO treatment, we estimate that a
sample size of N = 104 (i.e. n = 52 participants within each
sub-study with n = 26 in each treatment group) will reach
a ≥ 80% power for detecting a similar clinically relevant
differential change of 0.4 SD in the primary cognitive
composite outcome measure with a SD of this change of
0.5 between the treatment groups at an alpha level of 5%
(two-sided test). Based on our assumption of a 10%
drop-out rate from baseline to treatment completion, we
plan to recruit up to n = 58 for each sub-study to achieve
complete datasets for n = 52 participants per sub-study
(first-degree relatives and patients, respectively).
Data management and monitoring
All personal information will be obtained at the eligibil-
ity assessment or from patient records, if patients are
unable to provide the necessary pieces of information.
Written informed consent forms will be kept in a locked
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filing cabinet, while a password-protected list that
matches participant ID numbers with personal informa-
tion will be stored separate from pseudo-anonymized
data. The list matching participants’ personal informa-
tion with their ID number will be deleted and consent
forms maculated 10 years after study completion. At this
point, all data will be completely anonymized. All trial
authors will have access to the final trial dataset.
Pseudo-anonymized research data will be registered in
the Research Electronic Data Capture (REDCap) data-
base, which fulfills the Danish data law to keep research
participants’ records and meets GCP requirements for
data management. Study personnel involved in outcome
assessments and evaluation of these outcomes are
blinded to study medication until the data analyses are
completed. Consequently, blood sample results and lists
of potential adverse effects are registered in The Health-
care Platform (Sundhedsplatformen) to which only med-
ical doctors responsible for participant safety and the
person involved in blinding of the study medication have
access. REDCap has a logging module, which enables
tracking of the data entered. Data quality is ensured by
verification of data entered by outcome assessors and
score range restrictions on values from neuropsycho-
logical test and questionnaire results. All neuropsycho-
logical data for the primary outcome measure will be
double-checked by JZP.
Participant retention
All participants are offered feedback on the changes of
their neuropsychological performance across assessment
time points once they have completed the six-month
follow-up assessment. Furthermore, employed partici-
pants will be given a compensation of 100 DKK per hour
for 10 h of neuropsychological and fMRI assessments.
Travel expenses with public or private transportation are
reimbursed for all participants. Finally, patients will
benefit from the extra care they receive from study
nurses, psychologists, and medical doctors during their
participation.
Discussion
Summary
Cognitive dysfunction is a core feature of BD and UD,
which reduces socio-occupational functioning. The lack
of clinically available treatments with pro-cognitive effi-
cacy is partially related to major methodological chal-
lenges in this relatively new field, including the absence
of a sensitive brain-based biomarker model to select
among candidate treatments. Preclinical and clinical
studies point to EPO as one of the most promising can-
didate cognitive enhancement treatments, making it a
suitable potential treatment for assessment of neural ac-
tivity change associated with improvement of cognition.
The aim of the present trial is therefore twofold: (1) to
clarify whether 12 weekly EPO versus placebo (saline)
treatment has pro-cognitive effects in cognitively impaired
remitted patients with BD or recurrent UD and
first-degree relatives without mood or psychotic disorders
to patients with BD, recurrent UD, or schizophrenia; and
(2) to identify patterns of early treatment-related neural
activity change that may be predictive of subsequent cog-
nitive improvement.
Strengths
The present EPO trial includes, for the first time,
first-degree relatives with cognitive impairment (sub-study
1), which will clarify whether EPO has the potential to im-
prove cognitive and functional outcome in genetically pre-
disposed individuals, who are at increased risk of stress
and illness onset [86]. In general, the present trial (both
sub-studies) has several advantages over our previous
EPO cognition trial in BD and TRD [39, 40]. Notably, the
previous trial did not involve pre-screening for objectively
verified cognitive dysfunction, which may have introduced
type II errors since 30–50% of bipolar patients and 60–
80% of depressed patients are relatively cognitively intact
compared with neuropsychological test norms for
age-matched individuals, despite frequent subjective cog-
nitive complaints [1, 2, 87]. In the present trial, we will
therefore only include participants who present objective
cognitive dysfunction on a brief cognition screening tool
(SCIP) in keeping with the recent methodological recom-
mendations by the ISBD Targeting Cognition Task Force
[50]. Due to the cognitive heterogeneity characterizing re-
mitted patients with BD and UD [87], the ISBD Cognition
Task Force recommends a broad cognitive composite
score spanning attention, memory, and executive function
as primary outcome in cognition trials in mood disorders
[50]. In keeping with this, we have chosen the “speed of
complex cognitive processing” composite as the primary
outcome. While the longest follow-up in our previous
EPO trial was only six weeks after treatment completion,
we here include a six-month follow-up assessment to
assess whether any treatment-related cognitive improve-
ments persist long term. Further, the inclusion of
self-reported, observer-rated, and performance-based
measures of functional capacity will provide insight into
whether potential cognitive benefits of EPO translate into
improved daily functioning, which is the ultimate goal for
our patients. Finally, it is likely that the present expansion
of the treatment period from 8 to 12 weeks will result in
more robust and longer-lasting effects of EPO treatment.
Beyond EPO, the use of fMRI to assess early treatment-re-
lated change in neuronal activity within regions of the
“cognitive control network” and the correlation between
such change and subsequent cognitive improvement will
provide insight into the neurobiological targets of
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potential cognitive improvement and thus aid future treat-
ment development strategies [50, 88].
Limitations
The disadvantage of only enrolling participants with ob-
jectively verified cognitive dysfunction is that this limits
recruitment, since many patients with mood disorders
are relatively cognitively intact in comparison with
norms [1–3, 87]. For these reasons, we selected a cut-off
on the brief cognition screening tool (SCIP) to ensure
the presence of minimum subtle cognitive impairments
in this trial. Due to the extensive somatic co-morbidity
exclusion criteria, the study sample may not represent
the full range of BD and recurrent UD, which limits
generalizability of findings. However, this is necessary to
ensure participant safety, which is of principal import-
ance in the trial. Notwithstanding, this highlights the
major limitation of this treatment, since a large propor-
tion of patients have somatic co-morbidities and EPO
may therefore only become relevant for treatment of
cognitive impairments in a subgroup of patients (if the
study finds positive effects). This highlights a need for
development of other kinds of treatments to improve
cognition such as action-based cognitive remediation
(ABCR) [89]. The thorough assessments before and dur-
ing study participation may contribute to a selection of
participants who are more positive towards clinical re-
search and therefore also more willing to cooperate. In-
deed, this may partially explain the very high compliance
in our previous EPO trial, in which there was only one
drop-out [39]. Finally, patients with BD and recurrent
UD will be on medication for ethical reasons and to aid
generalizability of the results [50]. However, this con-
comitant pharmacological treatment may confound
neuropsychological test and fMRI task data due to pos-
sible effects of medications on cognition and BOLD re-
sponse [90]. We therefore seek to minimize confounding
effects by avoiding changes in patients’ concomitant
medication during the study period, if possible, and by
carefully recording their medication, so potential inter-
action effects with EPO can be assessed in post-hoc ana-
lyses. Further, we anticipate an equal distribution of
medications between treatment groups as in our previ-
ous EPO studies [39, 40], so any differences in cognition
and neural change between groups will be due to EPO
or saline.
Study feasibility
We have previously conducted a double-blinded ran-
domized trial of eight weeks of EPO treatment in 84 pa-
tients with mood disorders at the Psychiatric Centre
Copenhagen, Rigshospitalet. Based on this trial as well
as our collaboration on recruitment with other psychi-
atric centers and consultant psychiatrists in the Capital
Region of Denmark, we consider recruitment of 52–58
patients and 52–58 first-degree relatives over 30 months
to be feasible.
Safety procedures and monitoring of EPO infusions
EPO is a common treatment option for anemia patients
and has a good safety profile when carefully monitored.
However, hematopoietic effects of repeated EPO admin-
istration are associated with risk of hypertension and
blood clotting [91]. Indeed, EPO has been associated
with increased mortality in severely ill stroke patients
with previous thromboembolic disease, including pa-
tients given thrombolytic treatment [92, 93]. To ensure
participant safety in this trial, we therefore implement
extensive exclusion criteria to exclude candidates at in-
creased risk of thromboembolic events. Extremely rare
but serious side effects associated with long-term EPO
administration in patients with chronic severe somatic
diseases are thromboses at the site of dialysis in patients
with kidney failure, seizure, and potential tumor growth
[94]. The rare condition, pure red cell aplasia (PRCA),
has been detected with subcutaneous infusions and poor
packaging of the EPO medication. However, its inci-
dence rate has fallen to 0.3/100,000 patient years [95–
97]. Reticulocyte counts constitute the first indicator of
PRCA and are therefore thoroughly monitored. We ob-
served no serious adverse events in eight weeks of
weekly EPO infusions in the proposed dose and adminis-
tration form in our previous studies of 84 patients with
TRD or BD [39, 40]. EPO-related hematocrit levels in-
creased to an extent that necessitated blood-letting in
five (14%) of the 35 EPO-treated patients in weeks 3–8
(with one in week 3). This corresponds to observations
by Ehrenreich et al. [41, 42]. We discontinued EPO
treatment in six patients (17%) after 5–7 weeks due to
thrombocyte level increase (these participants completed
all assessments). Participant safety monitoring therefore
involves thorough medical examinations, systolic and dia-
stolic blood pressure measurement, blood sampling, elec-
trocardiography (ECG), and additional safety parameters
at baseline, weekly during the study, and at three weeks
after EPO/placebo treatment completion. Due to careful
adherence to the exclusion criteria and weekly safety mon-
itoring, we evaluate the risk of such side effects and ad-
verse events of EPO treatment to be extremely low in this
trial. Further, participants will be informed of all potential
adverse effects before randomization and are instructed
that iron supplements (which increase hematocrit levels)
are prohibited during the active treatment period. Al-
though the risk of potential thrombosis or suspected
PRCA is low, included participants are given a pocketsize
plastic card with instructions about what to do and con-
tact details to medical doctors at the local emergency de-
partment in case these symptoms appear. Participants stay
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at the clinic for observation for at least 30 min after each
infusion for a research nurse to monitor potential acute
side effects of EPO (e.g. rash at the infusion site or
headache).
Ethical considerations
We evaluate the risks and disadvantages of participating
in the study to be minimal based on previous EPO trials
[39, 40] and the described precautions, exclusion cri-
teria, and carefully established treatment plan in case of
side effects.
Although patients are not required to withdraw from
their usual antidepressant or mood stabilizing medica-
tion, they are requested not to change their doses or
treatment during the study course. This may give rise to
ethical considerations for the included remitted patients,
albeit we show consideration for their safety, rights, and
wellbeing by excluding those who are required to change
the type or dose of their mood stabilizing medical treat-
ment by their psychiatrist. In case of significant symp-
tom worsening, patients’ clinical needs, integrity, and
autonomy come before the scientific interests of the
study. Because of the lack of effective treatments target-
ing cognitive dysfunction in mood disorders [22, 98], the
use of a placebo group is necessary for investigating
potential beneficial cognitive effects of EPO. We are un-
able to offer active EPO treatment to these participants
after trial completion given the only preliminary evi-
dence for efficacy of EPO on cognition. This is likely to
be disappointing for the 50% of participants random-
ized to saline. The duration of neuropsychological test
assessments and mood ratings may lead to attrition in
some participants. However, we keep the duration of
neuropsychological assessments and fMRI scans to a
minimum to avoid attrition and reduce the risk of
drop-out. Albeit the procedure is safe and non-invasive,
some participants may experience it as claustrophobic
and anxiety provoking. For these reasons, we exclude
people, who suffer from claustrophobia from fMRI as-
sessments. Blood sampling may be associated with
slight discomfort but is routine hospital care. Partici-
pants will benefit from the extra care and close contact
with medical doctors, psychologists, and a research
nurse during study participations, which has demon-
strated beneficial effects [99]. Furthermore, the partici-
pation in the trial is considered beneficial for
first-degree relatives to patients with BD, recurrent UD,
or schizophrenia, since enrolment requires objectively
verified cognitive dysfunction, which is known to in-
crease psychiatric illness onset risk in these high-risk
individuals [20]. All participants are reimbursed for
their time and the transport expenses associated with
taking part in the study.
Perspectives
If the findings reveal pro-cognitive efficacy of EPO and
that this is associated with early prefrontal activity
change, this would (1) point to EPO as a candidate com-
pound targeting cognitive dysfunction in somatically
healthy patients with mood disorders and (2) highlight
prefrontal target engagement as a promising biomarker
model for pro-cognitive efficacy. From a methodological
perspective, such findings will be an important step in
future development of cognitive enhancement treat-
ments in neuropsychiatric disorders and preventive
strategies in at-risk populations, which could have sig-
nificant individual and societal implications.
Trial status and dissemination
Participant enrolment was initiated in September 2017
and is expected to continue until autumn 2020.
Follow-up data from the last recruitments will be col-
lected during the winter of 2021. Trial results will be
disseminated in peer-reviewed scientific journals and
presented at scientific conferences and meetings. Author
eligibility is assessed with the Vancouver Convention.
Additional file
Additional file 1: SPIRIT 2013 Checklist: Recommended items to address
in a clinical trial protocol and related documents*. (DOC 125 kb)
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